Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Up 275.7% in June

Context Therapeutics Inc. (NASDAQ:CNTX) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 3,211,049 shares, a growth of 275.7% from the June 15th total of 854,672 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average trading volume of 4,938,871 shares, the days-to-cover ratio is presently 0.7 days.

Context Therapeutics Stock Down 4.5%

NASDAQ CNTX traded down $0.03 during mid-day trading on Monday, hitting $0.62. The stock had a trading volume of 3,434,974 shares, compared to its average volume of 5,103,142. The company has a 50 day simple moving average of $1.57 and a 200 day simple moving average of $2.03. The company has a market cap of $57.31 million, a price-to-earnings ratio of -1.49 and a beta of 1.75. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. As a group, equities analysts anticipate that Context Therapeutics will post -0.39 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Piper Sandler boosted their target price on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Maxim Group cut their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Guggenheim reiterated a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Context Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors have recently made changes to their positions in CNTX. Sanctuary Advisors LLC acquired a new position in Context Therapeutics in the 1st quarter valued at about $51,000. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter worth approximately $43,000. Quadrature Capital Ltd acquired a new position in shares of Context Therapeutics in the 4th quarter valued at $68,000. OMERS ADMINISTRATION Corp purchased a new stake in Context Therapeutics during the first quarter valued at about $211,000. Finally, XTX Topco Ltd grew its holdings in shares of Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after purchasing an additional 91,008 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.